The FDA is updating federal regulations to recognize alternatives to animal experimentation. As a December 7 public comment deadline approaches, the changes raise questions about scientific progress, transparency, and the power of language.
Words matter, particularly when they appear in federal regulations that influence how scientific research is conducted. A seemingly minor change in terminology can reflect a broader shift in policy, opening doors to new approaches while raising questions about what may be lost in translation.
On September 22, 2026, the U.S. Food and Drug Administration published a direct final rule titled Nonclinical Testing Terminology. The rule replaces certain references to animal tests and studies in federal drug and biological product regulations with broader terminology encompassing both animal and nonanimal research methods. The agency describes the changes as largely administrative, intended to align existing regulations with federal law and remove language that emphasizes animal experimentation where other scientifically valid approaches may be available.
For those advocating an end to animal experimentation, the development presents both an opportunity and an important ethical question. Recognizing alternatives within federal regulations is a meaningful step toward reducing reliance on animals, but does replacing the word animal with nonclinical also risk making the individuals subjected to experiments less visible?
A Change in Language, Not Yet in Practice
For decades, animal experimentation has occupied a prominent place in the development and safety evaluation of pharmaceuticals. Regulatory language frequently referenced animal studies, reinforcing their position within established research practices even as scientists developed increasingly sophisticated alternatives.
The FDA’s terminology changes follow amendments enacted through the Food and Drug Omnibus Reform Act of 2022 (FDORA), part of the Consolidated Appropriations Act, 2023. Those amendments broadened federal recognition of nonclinical testing methods, including cell-based assays, organ-on-a-chip technologies, computer modeling, and other approaches that do not necessarily involve living animals.
Collectively, many of these emerging approaches are known as New Approach Methodologies, or NAMs. Rather than relying exclusively on experiments involving other species, researchers can increasingly investigate aspects of human biology using human-derived cells, engineered tissues, computational systems, and other technologies designed to provide relevant scientific information.
The FDA’s updated terminology acknowledges that these approaches may satisfy applicable regulatory requirements when scientifically appropriate. Importantly, however, the agency’s definition of nonclinical testing continues to include animal experiments. The rule does not prohibit animal testing, establish a timetable for eliminating it, or require pharmaceutical companies to adopt alternatives. In fact, the FDA states that the changes impose no new requirements and are not expected to alter existing industry practices.
This distinction matters. Removing regulatory language that appears to favor animal experimentation may help create space for alternatives, but the change itself does not guarantee that fewer animals will be used.
The Individuals Behind the Terminology
There is another dimension to this discussion that deserves consideration beyond regulatory efficiency and scientific innovation: the individuals whose lives are affected by these practices.
A mouse confined to a laboratory, a beagle subjected to repeated procedures, or a monkey restrained for experimentation does not experience those circumstances as a scientific category. Each is a sentient individual whose experiences exist independently of the terminology researchers and regulators use to describe them.
Within scientific and regulatory settings, however, animals are frequently represented through technical language emphasizing experimental models, biological responses, and research outcomes. Such terminology serves practical purposes, allowing scientists to communicate complex information with precision. Yet it can also create distance between the procedures being discussed and the living beings subjected to them.
The term nonclinical is not inherently misleading. It accurately describes research conducted outside human clinical trials and can encompass a variety of testing approaches. Nevertheless, when the same term describes both a computer simulation and an experiment performed on a living animal, important ethical distinctions can become less apparent to readers unfamiliar with the underlying methods.
This is not evidence that the FDA intends to conceal animal experimentation. Its stated purpose is to recognize a broader range of scientifically valid testing methods. The concern is instead one of transparency: whether the language used to describe research allows the public to understand clearly when animals remain involved.
Scientific progress and ethical accountability should not be competing priorities. Regulatory language can recognize new technologies while preserving clarity about the methods being used and the individuals affected by them.
The Scientific Case for Moving Beyond Animal Testing
The movement toward nonanimal research methods is not driven solely by ethical concerns. It also reflects longstanding scientific questions about the limitations of using one species to predict biological responses in another.
Differences in physiology, metabolism, and disease processes can complicate the translation of animal research findings into human outcomes. Although animal studies have contributed to biomedical research, their predictive limitations have encouraged scientists to develop methods that more directly reflect human biology.
Human-cell-based systems, organoids, organ-on-a-chip technologies, and computational models offer opportunities to study biological processes in ways that may improve the relevance of certain safety assessments. These methods also present opportunities to reduce or replace animal use, although their suitability and validation vary depending on the research question.
The FDA has increasingly acknowledged the potential of these technologies, and the September rule reflects that broader scientific direction. By updating regulations that previously emphasized animal studies, the agency may help remove unnecessary barriers to the consideration of alternative approaches.
Still, regulatory permission and widespread scientific adoption are different things. Meaningful progress will depend on continued investment, rigorous validation, institutional willingness to change established practices, and regulatory decisions that support scientifically appropriate alternatives.
For advocates seeking an end to animal experimentation, the challenge is ensuring that recognition of these methods becomes a foundation for measurable change rather than an endpoint in itself.
Why Public Comments Matter
The FDA published its terminology changes through a process known as direct final rulemaking, generally used when an agency anticipates that proposed amendments will be noncontroversial. A companion proposed rule was published simultaneously, allowing the agency to continue through the ordinary rulemaking process if significant adverse comments are received.
The direct final rule is currently scheduled to take effect on February 4, 2027. However, if the FDA receives significant adverse comments, it intends to withdraw that rule and consider the issues through the companion proposal.
The public has until December 7, 2026, to submit comments.
The National Lawyers Guild’s New York City Animal Rights Committee has been encouraging public participation in the rulemaking, drawing attention to the terminology changes and their implications for animal experimentation.
Understanding how federal public comments work is especially important here. Contrary to a common misconception, regulatory comment periods are not public votes in which the largest number of submissions automatically determines the outcome. Federal agencies evaluate comments for their relevance, substance, and relationship to the proposed regulatory action.
Research into the federal public comment process demonstrates why this distinction matters. Agencies routinely receive large numbers of identical or substantially similar submissions, which may be grouped for review. While widespread public participation can communicate the level of public interest in an issue, the substance of a comment is particularly important when an agency must evaluate whether its proposal is legally, scientifically, or administratively justified.
A well-developed comment may identify a problem with proposed language, provide scientific evidence, explain an overlooked consequence, or recommend a specific revision. Substantive comments can influence regulatory decisions and become part of the administrative record, creating a documented basis for further scrutiny.
For this particular rulemaking, comments addressing the clarity of the proposed terminology, its implications for transparency, or the regulatory treatment of animal and nonanimal testing methods may be especially relevant. Those raising objections should explain specifically how the proposed language could be improved, rather than relying solely on generalized opposition to animal experimentation.
The FDA has also explained that comments challenging the premise or effectiveness of the rule may qualify as significant adverse comments if they raise issues requiring a substantive response. This makes thoughtful, well-supported participation particularly important.
Readers can review the Federal Register notice and submit comments using docket number FDA-2026-N-5347. Electronic comments must be submitted by 11:59 p.m. Eastern Time on December 7. Submissions generally become publicly accessible, so participants should avoid including personal or confidential information they do not wish to disclose.
Beyond the Words
The FDA’s terminology changes reflect an evolving scientific landscape in which animal experimentation is no longer the only approach recognized within certain regulatory provisions. That recognition creates opportunities for researchers developing alternatives and for advocates seeking a future in which scientific progress does not depend on the exploitation of other species.
Yet the ethical significance of this moment extends beyond the wording of federal regulations. A system can adopt more inclusive scientific terminology while continuing practices that raise serious questions about necessity, suffering, and the moral consideration afforded to other animals.
The challenge is to ensure that regulatory modernization is accompanied by transparency, accountability, and meaningful efforts to replace animal experimentation wherever scientifically possible.
Language can influence how institutions operate, how scientists approach their work, and how the public understands what is being done. In this case, changing the language may help expand the possibilities for research without animals.
Whether those possibilities become lasting progress will depend on what happens beyond the words.
